Impedimed (ASX:IPD) Tax Provision : A$-0.03 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Impedimed Tax Provision?

Impedimed's tax provision for the six months ended in Dec. 2023 was A$-0.02 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.03 Mil.

Impedimed Tax Provision Historical Data

The historical data trend for Impedimed's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Impedimed Tax Provision Chart

Impedimed Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Tax Provision

Get a 7-Day Free Trial

-0.05

-0.04

-0.05

-0.03

Impedimed Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Tax Provision	Get a 7-Day Free Trial															-0.02	-0.03	-0.02	-0.01	-0.02

Impedimed Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.03 Mil.

Impedimed (ASX:IPD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Impedimed Ltd (ASX:IPD) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

IPDQF:USA

Address

50 Parker Court, Unit 1, Pinkenba, QLD, AUS, 4008

Website

https://www.impedimed.com

Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates most of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The Company recognizes revenue from stand alone sale of Legacy Devices and Consumables, Sale of SOZO Device and Software Subscription Services.

Impedimed (ASX:IPD) Headlines

No Headlines